TY  - JOUR
ID  - pittir22306
UR  - http://d-scholarship-dev.library.pitt.edu/22306/
IS  - 3
A1  - Goff, JP
A1  - Epperly, MW
A1  - Dixon, T
A1  - Wang, H
A1  - Franicola, D
A1  - Shields, D
A1  - Wipf, P
A1  - Li, S
A1  - Gao, X
A1  - Greenberger, JS
Y1  - 2011/01/01/
N2  - Background/Aim: Total-body irradiation (TBI) doses in the range of 2-8 Gy are associated with a drop in peripheral blood counts, decreased bone marrow cellularity, and hematopoietic syndrome. Radiation mitigators must be safe for individuals likely to recover spontaneously. Materials and Methods: Female C57BL/6HNsd mice exposed to 9.0 and 9.15 Gy TBI, received intraperitoneal (10 mg/kg) JP4-039, a novel radiation mitigator, 24 hours after irradiation and were followed for hematopoietic recovery. Results: Irradiated mice showed reduced peripheral blood lymphocytes and neutrophils and bone marrow cellularity at day 5. Serum electrolytes, liver and renal function tests showed no deleterious effect of JP4-039-after irradiation, and no reduction in survival compared to irradiated controls. Marrow recovery measured as cellularity, and hematopoietic colony-forming cells including primitive granulocyte-erythroid-megakaryocyte- monocytes (GEMM), reached pre-irradiation levels by day 30 in JP4-039 treated groups. Mice receiving single or multiple administrations of JP4-039 showed an early return of CFU-GEMM. Conclusion: JP4-039 (GS-Nitroxide) is a safe radiation mitigator in mice warranting studies in larger animals and potentially a Phase I Clinical Trial.
JF  - In Vivo
VL  - 25
SN  - 0258-851X
TI  - Radiobiologic effects of GS-nitroxide (JP4-039) on the hematopoietic syndrome
SP  - 315 
AV  - public
EP  -  323
ER  -